176 related articles for article (PubMed ID: 17627234)
21. ADENOSINE INFLUENCES FOXP3 EXPRESSION OF T REGS VIA THE A2AR/CREB PATHWAY IN A MOUSE MODEL OF SEPSIS.
Zhang T; Fu W; Liu D; He Y; Wang J; Ma T
Shock; 2024 Jun; 61(6):924-933. PubMed ID: 38010286
[TBL] [Abstract][Full Text] [Related]
22. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.
Kono K; Kawaida H; Takahashi A; Sugai H; Mimura K; Miyagawa N; Omata H; Fujii H
Cancer Immunol Immunother; 2006 Sep; 55(9):1064-71. PubMed ID: 16328385
[TBL] [Abstract][Full Text] [Related]
23. An Evaluation of T-Regulatory Cells and Inflammatory Cytokines in Preeclampsia.
Koppisetty BK; Dash P; Saharia GK; Nayak S; Jena SK
Cureus; 2023 Aug; 15(8):e43379. PubMed ID: 37700972
[TBL] [Abstract][Full Text] [Related]
24. Baicalin, a natural compound, promotes regulatory T cell differentiation.
Yang J; Yang X; Li M
BMC Complement Altern Med; 2012 May; 12():64. PubMed ID: 22591709
[TBL] [Abstract][Full Text] [Related]
25. Should we use extracorporeal photopheresis more often? Evidence from graft-versus-host disease patients monitored with Treg as a biomarker.
Lopes SM; Roncon S; Pinho AC; Bordalo F; Antunes L; Campilho F; Campos A; Costa-Pereira A
Future Sci OA; 2020 Aug; 6(8):FSO623. PubMed ID: 32983569
[TBL] [Abstract][Full Text] [Related]
26. Lower frequency of CD62L(high) and higher frequency of TNFR2(+) Tregs are associated with inflammatory conditions in type 1 diabetic patients.
Ryba M; Rybarczyk-Kapturska K; Zorena K; Myśliwiec M; Myśliwska J
Mediators Inflamm; 2011; 2011():645643. PubMed ID: 21584225
[TBL] [Abstract][Full Text] [Related]
27. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection.
Feng G; Nadig SN; Bäckdahl L; Beck S; Francis RS; Schiopu A; Whatcott A; Wood KJ; Bushell A
Sci Transl Med; 2011 May; 3(83):83ra40. PubMed ID: 21593400
[TBL] [Abstract][Full Text] [Related]
28. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer.
Baratelli F; Lee JM; Hazra S; Lin Y; Walser TC; Schaue D; Pak PS; Elashoff D; Reckamp K; Zhang L; Fishbein MC; Sharma S; Dubinett SM
Am J Transl Res; 2010 Jun; 2(4):356-67. PubMed ID: 20733946
[TBL] [Abstract][Full Text] [Related]
29. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
Waldron-Lynch F; Henegariu O; Deng S; Preston-Hurlburt P; Tooley J; Flavell R; Herold KC
Sci Transl Med; 2012 Jan; 4(118):118ra12. PubMed ID: 22277969
[TBL] [Abstract][Full Text] [Related]
30. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
Salhotra A; Falk L; Park G; Sandhu K; Ali H; Modi B; Hui S; Nakamura R
Expert Rev Clin Immunol; 2024 Feb; 20(2):169-184. PubMed ID: 37921226
[TBL] [Abstract][Full Text] [Related]
31. Perspectives on Regulatory T Cell Therapies.
Probst-Kepper M; Kröger A; Garritsen HS; Buer J
Transfus Med Hemother; 2009; 36(5):302-308. PubMed ID: 21076548
[TBL] [Abstract][Full Text] [Related]
32. Evaluating CD4 and Foxp3 mRNA Expression in Tissue Specimens of Celiac Disease and Colorectal Cancer Patients.
Asri N; Nazemalhosseini Mojarad E; Taleghani MY; Houri H; Saeedi Niasar M; Rezaei-Tavirani M; Jahani-Sherafat S; Shahbazkhani A; Nikzamir A; Ehsani Ardakani MJ; Khodadost M; Rostami-Nejad M
Asian Pac J Cancer Prev; 2024 Feb; 25(2):647-652. PubMed ID: 38415552
[TBL] [Abstract][Full Text] [Related]
33. Lymphoid tissue inducer cells: pivotal cells in the evolution of CD4 immunity and tolerance?
Lane PJ; Gaspal FM; McConnell FM; Withers DR; Anderson G
Front Immunol; 2012; 3():24. PubMed ID: 22566908
[TBL] [Abstract][Full Text] [Related]
34. Collection efficiency of mononuclear cells in offline extracorporeal photopheresis: can processing time be shortened?
Kartal O; Lindlbauer N; Laner-Plamberger S; Rohde E; Foettinger F; Ombres L; Zimmermann G; Mrazek C; Lauth W; Grabmer C
Blood Transfus; 2024 Mar; 22(2):150-156. PubMed ID: 37458722
[TBL] [Abstract][Full Text] [Related]
35. Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers.
Bojanic I; Worel N; Pacini CP; Stary G; Piekarska A; Flinn AM; Schell KJ; Gennery AR; Knobler R; Lacerda JF; Greinix HT; Pulanic D; Crossland RE
Front Immunol; 2023; 14():1086006. PubMed ID: 36875063
[TBL] [Abstract][Full Text] [Related]
36. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.
Buxbaum NP; Socié G; Hill GR; MacDonald KPA; Tkachev V; Teshima T; Lee SJ; Ritz J; Sarantopoulos S; Luznik L; Zeng D; Paczesny S; Martin PJ; Pavletic SZ; Schultz KR; Blazar BR
Blood Adv; 2023 Sep; 7(17):4886-4902. PubMed ID: 36322878
[TBL] [Abstract][Full Text] [Related]
37. Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.
Kostareva I; Kirgizov K; Machneva E; Ustyuzhanina N; Nifantiev N; Skvortsova Y; Shubina I; Reshetnikova V; Valiev T; Varfolomeeva S; Kiselevskiy M
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145321
[TBL] [Abstract][Full Text] [Related]
38. Immune Monitoring Assay for Extracorporeal Photopheresis Treatment Optimization After Heart Transplantation.
Dieterlen MT; Klaeske K; Bernhardt AA; Borger MA; Klein S; Garbade J; Lehmann S; Ayuk FA; Reichenspurner H; Barten MJ
Front Immunol; 2021; 12():676175. PubMed ID: 34447372
[TBL] [Abstract][Full Text] [Related]
39. Apoptotic Donor Cells in Transplantation.
Husain I; Luo X
Front Immunol; 2021; 12():626840. PubMed ID: 33717145
[TBL] [Abstract][Full Text] [Related]
40. [UV phototherapy : UV phototherapy and photodiagnostics-a practical overview].
Stege H; Ghoreschi K; Hünefeld C
Hautarzt; 2021 Jan; 72(1):14-26. PubMed ID: 33394067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
